

539, 385

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number  
**WO 2004/056369 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/55**,  
C07D 223/16, 401/12, 403/12, A61P 25/00, C07D 401/14,  
413/14, 417/14, 409/14, 417/12, 409/12, 413/12, 471/04,  
491/04, 403/14

Essex CM19 5AW (GB). **WITHERINGTON, Jason**  
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park  
South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(21) International Application Number:  
PCT/EP2003/014556

(74) Agent: **GIBSON, Mark**; GlaxoSmithKline, Corporate In-  
tellectual Property, CN925.1, 980 Great West Road, Brent-  
ford, Middlesex TW8 9GS (GB).

(22) International Filing Date:  
18 December 2003 (18.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:  
0229820.6 20 December 2002 (20.12.2002) GB  
0312607.5 2 June 2003 (02.06.2003) GB

(84) Designated States (*regional*): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **GLAXO  
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,  
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BAMFORD, Mark,**  
**James** [GB/GB]; GlaxoSmithKline, New Frontiers Sci-  
ence Park South, Third Avenue, Harlow, Essex CM19 5AW  
(GB). **DEAN, David, Kenneth** [GB/GB]; GlaxoSmithK-  
line, New Frontiers Science Park South, Third Avenue,  
Harlow, Essex CM19 5AW (GB). **SEHMI, Sanjeet, Singh**  
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park  
South, Third Avenue, Harlow, Essex CM19 5AW (GB).  
**WILSON, David, Matthew** [GB/GB]; GlaxoSmithKline,  
New Frontiers Science Park South, Third Avenue, Harlow,

## Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: BENZO-DIAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

(57) Abstract: The present invention relates to benzazepine derivatives of formula (I) wherein: R<sup>1</sup> represents -C<sub>3-7</sub> cycloalkyl optionally substituted by C<sub>1-3</sub> alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

WO 2004/056369 A1